Yahoo Finance

Market Cap: A$237.71M

Helloworld Travel Limited, with a market cap of A$237.71 million, operates in the travel distribution sector with significant revenue streams from Australia and New Zealand. Despite recent earnings decline, the company remains debt-free and maintains strong asset coverage over liabilities. The dividend yield of 7.53% is not well-supported by free cash flow, raising sustainability concerns despite a recent increase to A$0.08 per share. Trading at a price-to-earnings ratio of 9.1x, below the Australian market average, it presents as relatively undervalued with analysts forecasting potential stock price growth of 67%. Management's experience averages 2.9 years, providing moderate stability amidst industry challenges.

• Click to explore a detailed breakdown of our findings in Helloworld Travel's financial health report.

• Evaluate Helloworld Travel's prospects by accessing our earnings growth report.

Imugene

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Imugene Limited is an Australian clinical stage immuno-oncology company focused on developing immunotherapies to activate the immune system against cancer, with a market cap of A$194.14 million.

Operations: Imugene's revenue segment is primarily focused on the research, development, and commercialisation of health technologies with a reported figure of -A$1.84 million.

Market Cap: A$194.14M

Imugene Limited, with a market cap of A$194.14 million, is pre-revenue and unprofitable, reporting a net loss of A$48.34 million for the half-year ending December 2024. Despite this, its short-term assets significantly exceed liabilities, and it holds more cash than total debt. The company recently appointed Darren Keamy as CFO and Company Secretary, bringing extensive biopharmaceutical financial expertise to potentially enhance strategic direction. Imugene was added to the S&P/ASX Emerging Companies Index but dropped from other indices in March 2025. Shareholder dilution has been minimal over the past year amidst ongoing capital raises for operational funding.

• Jump into the full analysis health report here for a deeper understanding of Imugene.

• Gain insights into Imugene's future direction by reviewing our growth report.

Make It Happen

• Investigate our full lineup of 988 ASX Penny Stocks right here.

• Ready For A Different Approach? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:BKY ASX:HLO and ASX:IMU.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com